IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

Eli Lilly to sign $2 billion AI drug discovery deal

Eli Lilly is reportedly signing a $2 billion agreement with Hong Kong-based Insilico Medicine. The deal grants Lilly rights to sell a new GLP-1 diabetes drug.

Xurve View
Insights:

Eli Lilly and Company is reportedly nearing a $2 billion agreement with Insilico Medicine, a biotechnology firm specializing in the use of artificial intelligence for pharmaceutical discovery. According to a report from the Financial Times, the deal underscores a significant investment in AI-driven healthcare solutions.

An aerial perspective captures the Eli Lilly corporate logo at its facility in San Diego, California, taken in late 2025. REUTERS/Mike Blake
IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and analytics platform providing news, market data, analytical tools, and AI-powered features for informational and educational purposes. The Services and information provided do not constitute investment advice, trading signals, or brokerage services. Investing involves risk, and Users should carefully evaluate information before making investment decisions.